Lantheus (NASDAQ:LNTH) Cut to Hold at StockNews.com

StockNews.com lowered shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a report released on Thursday.

LNTH has been the subject of several other reports. Truist Financial reiterated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. B. Riley upped their target price on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Stock Performance

NASDAQ:LNTH opened at $90.52 on Thursday. The stock has a market cap of $6.29 billion, a price-to-earnings ratio of 15.06 and a beta of 0.51. Lantheus has a one year low of $50.20 and a one year high of $126.89. The business’s 50-day simple moving average is $103.13 and its 200 day simple moving average is $96.93.

Institutional Trading of Lantheus

A number of institutional investors and hedge funds have recently made changes to their positions in LNTH. Signaturefd LLC increased its position in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares during the period. Silverberg Bernstein Capital Management LLC increased its holdings in shares of Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after acquiring an additional 100 shares during the period. UMB Bank n.a. lifted its position in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the last quarter. GAMMA Investing LLC boosted its stake in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares during the period. Finally, Moody National Bank Trust Division grew its position in Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after purchasing an additional 162 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.